Home »

Near Term Catalyst Has ArQule Poised for a Move Up

LOS ANGELES, CA — (Marketwire) — 12/18/12 — ArQule, Inc. engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes.The firm-s lead product candidate Tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase 3 clinical trial for the treatment of liver cancer and colorectal cancer (CRC). The company also develops ARQ 621, an inhibitor of the Eg5 kinesin motor protein that has completed Phase I t

Analytics

© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de